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ABSTRACT
One of the major obstacles in non-viral gene
transfer is the nuclear membrane. Attempts to
improve the transport of DNA to the nucleus through
the use of nuclear localization signals or importin-b
have achieved limited success. It has been pro-
posed that the nuclear pore complexes (NPCs)
through which nucleocytoplasmic transport occurs
are filled with a hydrophobic phase through which
hydrophobic importins can dissolve. Therefore,
considering the hydrophobic nature of the NPC
channel, we evaluated whether a non-selective
gating of nuclear pores by trans-cyclohexane-
1,2-diol (TCHD), an amphipathic alcohol that rever-
sibly collapses the permeability barrier of the NPCs,
could be obtained and used as an alternative
method to facilitate nuclear entry of plasmid DNA.
Our data demonstrate for the first time that TCHD
makes the nucleus permeable for both high mole-
cular weight dextrans and plasmid DNA (pDNA) at
non-toxic concentrations. Furthermore, in line with
these observations, TCHD enhanced the transfec-
tion efficacy of both naked DNA and lipoplexes. In
conclusion, based on the proposed structure of
NPCs we succeeded to temporarily open the NPCs
for macromolecules as large as pDNAs and demon-
strated that this can significantly enhance non-viral
gene delivery.
INTRODUCTION
Viral vectors are eﬃcient DNA delivery systems as they
possess natural mechanisms to enter cells, to escape from
endosomes and to transport their DNA into the nucleus.
However, they also display important disadvantages, such
as immunogenic response and safety risks when adminis-
tered to patients. Non-viral carriers lack these disadvan-
tages, but poor transfection eﬃciencies currently limit the
usefulness of these vectors for gene therapy applications.
The low gene transfer capacity of non-viral vectors is
mainly due to their inability to translocate the therapeutic
DNA into the cell nucleus. Indeed, it has been shown that
microinjection of plasmid DNA (pDNA) in the cytoplasm
of non-dividing cells resulted in 51% gene expression,
while a massive gene expression occurred when the pDNA
was injected in the nucleus (1–3). In dividing cells the
nuclear envelope disassembles on a regular base, which
oﬀers an opportunity for DNA to enter the nucleus (4–6).
However, the DNA that is waiting in the cytoplasm for
the next cell division is sensitive to degradation by
nucleases. Therefore, methods that can enhance the
nuclear uptake of DNA into nuclei of both non-dividing
and dividing cells are urgently needed in non-viral-based
gene therapy.
Nucleocytoplasmic transport proceeds through the
nuclear pore complexes (NPCs) which form channels in
the nuclear envelope with a diameter of 40nm (7,8).
Vertebrate NPCs have a mass of 125MDa and contain
30–50 diﬀerent proteins, which are called nucleoporins.
Small molecules with a molecular weight up to 30kDa can
passively diﬀuse through the NPC. In contrast, the
translocation of larger macromolecules into the nucleus
occurs via an active mechanism involving nuclear trans-
port receptors. The majority of the nuclear transport
pathways are mediated by receptors of the importin
family. Proteins or other cargo molecules that carry a
classical nuclear localization sequence (NLS) are recog-
nized by importin-a, which subsequently forms a complex
through its importin-b-binding domain with importin-b
(9). NLSs can be highly diverse in nature and range
from the short bipartite classical NLS to extended
protein domains, as is the case for histones or ribosomal
proteins (10). To promote the nuclear import of DNA,
NLS peptides, NLS-containing proteins and even
importin-b (11) have been attached to DNA via several
strategies: electrostatic (12–17) or covalent (18–22) bind-
ing, via protein–DNA interaction (23,24), via PNA clamps
(15,25–27) and coupled to polymers (28–30), lipids (31–36)
or recombinant lambda phage (37). Nevertheless, all these
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through the use of NLSs or importin-b have achieved only
limited success.
It has recently been shown that the nuclear uptake of
macromolecules can be enhanced signiﬁcantly by addition
of the amphipathic molecule trans-cyclohexane-1,2-diol
(TCHD) (38). The mechanism by which TCHD causes
nuclear localization of macromolecules can be explained
based on the inner channel properties of the nuclear pores.
It is believed that these nuclear pores are ﬁlled with a
hydrophobic phase through which importins, but not inert
hydrophilic substrates, can dissolve. The addition of
TCHD causes a temporary, non-selective gating of the
pore and allows passage of molecules which would
otherwise be rejected from passage. In other words, a
non-selective gating of the nuclear pore channel by TCHD
renders the actual translocation through the pore channel
independent of nuclear transport receptors. This can be
explained by the fact that TCHD causes disruption of the
hydrophobic interactions between the hydrophobic phe-
nylalanine–glycine repeats of the nucleoporines, which
consequently causes collapsing of the permeability barrier
of the NPCs. Importantly, the eﬀect of TCHD is reversible
and does not cause damage of the nuclear pores (38).
In this paper we studied whether a non-selective gating
of nuclear pores by amphipathic molecules like TCHD
could also be used as an alternative method to facilitate
nuclear entry of plasmid DNA. Therefore, we examined
the eﬀect of TCHD (a) on the nuclear import of
macromolecules and pDNA and (b) on the transfection
eﬃciency of naked pDNA and non-viral nanoparticles,
such as poly- and lipoplexes. In summary, we found that
TCHD was able to make the nuclear membrane perme-
able for both high molecular weight dextrans and pDNA
at non-toxic concentrations. Furthermore, TCHD
enhanced the transfection eﬃciency of both naked
pDNA and DOTAP:DOPE-based lipoplexes, but had no
eﬀect on the linear PEI-based polyplexes.
MATERIALS AND METHODS
Materials
Dulbecco’s modiﬁed Eagle’s medium (DMEM),
L-glutamine (L-Gln), heat-inactivated fetal bovine serum
(FBS), phosphate-buﬀered saline (PBS) and penicillin/
streptomycin (P/S) were supplied by GibcoBRL
(Merelbeke, Belgium). The secreted alkaline phosphatase
(SEAP) expression plasmid was a kind gift from
Prof. Dr Tavernier (Ghent University, Belgium) and
22kDa linear polyethyleneimine (PEI) from Prof.
Dr Wagner (University of Munich, Germany). The
pGL3-control plasmid and luciferase assay kit were
obtained from Promega (Leiden, The Netherlands).
One hundred ﬁfty-eight kilodaltons of tetramethylrhoda-
mine isothiocyanate-labeled dextran (TRITC-dextran)
and TCHD were purchased from Sigma Aldrich.
1,2-dioleoyl-3-trimethylammonium-propane (DOTAP)
chloride salt, 1,2-dilinoleoyl-sn-glycero-3-
phosphoethanolamine (DOPE) and 1,2-distearoyl-sn-
glycero-3-phosphoethanolamine-N-[Amino(Polyethylene
Glycol)2000] (DSPE-PEG2000) were obtained from Avanti
Polar Lipids (Alabaster, AL, USA).
Cell culture
A549 (lung carcinoma cells; ATCC number CCL-185) and
Vero (Africangreenmonkeycells; ATCC numberCCL-81)
cellswereculturedinDMEMcontaining2mM L-Gln,10%
heat-inactivated FBS, 100U/ml P/S and grown at 378Ci n
a humidiﬁed atmosphere containing 5% CO2.
Fluorescent labeling ofpDNA
Plasmid DNA was covalently labeled with Cy5 using the
LabelIT kit of Mirus Corporation (Madison, WI, USA)
according to the manufacturer’s recommendations.
Brieﬂy, LabelIT reagent, containing Cy5, and 100mg
DNA were mixed in 1ml Hepes buﬀer (20mM Hepes,
pH 7.4) at Cy5:DNA ratio (w:w) of 0.5:1 and incubated at
378C for 1h. Subsequently, the labeled pDNA was
separated from unattached label by precipitation in the
presence of ethanol and 0.5M NaCl and reconstituted in
20mM Hepes buﬀer (pH 7.4).
Microinjection studies
Microinjection studies were conducted using a Femtojet
microinjector and an Injectman NI 2 micromanipulator
(Eppendorf, Hamburg, Germany). Vero cells were chosen
for these microinjection experiments as they have a well-
deﬁned nucleus and large cytoplasm. Vero cells (2.510
4
cells/cm
2) were plated onto sterile glass bottom culture
dishes (MatTek Corporation, MA, USA) and allowed to
adhere for 1day. The cells were then washed with PBS and
transferred into 2ml serum-free medium supplemented
with 20mM Hepes (pH 7.4) to improve the buﬀering
capacity of the medium during microinjection. Five
microliters 158kDa TRITC-dextran (1mg/ml) or
Cy5-labeled pDNA (1mg/ml) was back-loaded into
Femptotip II microinjection needles and cells were
injected using an injection pressure of 100psi, a back-
pressure of 30–50psi and injection duration of 0.5s.
Where mentioned, the medium was replaced after micro-
injection by TCHD-containing serum-free medium, sup-
plemented with 20mM Hepes (pH 7.4).
To determine the cellular distribution, the ﬂuorescence
in the cells was visualized on diﬀerent time points after
microinjection using a Nikon C1si confocal laser scanning
module attached to a motorized Nikon TE2000-E inverted
microscope (Nikon Benelux, Brussels, Belgium). With a
60 water immersion objective and the 561 and 638nm
laser lines for the excitation of the TRITC and Cy5 label,
respectively. A non-confocal diascopic DIC (diﬀerential
interference contrast) image was collected simultaneously
with the confocal images.
For the z-scan analysis of the ﬂuorescence after
cytoplasmic microinjection of the Cy5-labeled pDNA
(Cy5-pDNA), the confocal volume (1ﬂ) of a BioRad
MRC 1024 CLSM (Hemel Hempstadt, UK) equipped
with the ConfoCor 2 ﬂuorescence correlation spectro-
scopy (FCS) setup (LSM510 ConfoCor 2, Zeiss,
Go ¨ ttingen, Germany) was positioned in a randomly
selected site in the nucleus. The ﬂuorescence, along the
e86 Nucleic Acids Research, 2007, Vol. 35, No. 12 PAGE2 OF10z-axis at this selected XY site and perpendicular to the cell
surface, was recorded with the avalanche photodiodes of
the ConfoCor 2 system before and every 10min after
addition of 1% (w/v) TCHD dissolved in serum-free
medium supplemented with 20mM Hepes (pH 7.4).
Preparation of polyplexes and lipoplexes
Polyplexes consisting of 22kDa linear PEI were prepared
as described by Fayazpour et al. (39). Brieﬂy, polyplexes
were prepared in 20mM Hepes pH 7.4 by adding the PEI
all at once to the pDNA at a N/P ratio of 10.
Subsequently, the mixture was vortexed for 10s and the
polyplexes were allowed to equilibrate for 30min at room
temperature prior to use. The ﬁnal pDNA concentration
in the polyplexes was 0.126mg/ml.
Liposomes composed of DOTAP:DOPE:DSPE-
PEG2000 (molar ratio 5:5:0.2) were prepared as described
previously (40). Brieﬂy, appropriate amounts of lipids
were dissolved in chloroform and mixed. The chloroform
was subsequently removed by rotary evaporation at 378C
followed by ﬂushing the obtained lipid ﬁlm with nitrogen
during 30min at room temperature. The dried lipids were
then hydrated by adding Hepes buﬀer till a ﬁnal lipid
concentration of 10.2mM. After mixing in the presence of
glass beads, liposome formation was allowed overnight
at 48C. Thereafter, the formed liposomes were extruded
11 times through two stacked 100nm polycarbonate
membrane ﬁlters (Whatman, Brentfort, UK) at room
temperature using an Avanti Mini-Extruder (Avanti Polar
Lipids). The extruded liposomes were subsequently mixed
with pDNA in a charge ratio of 4 and incubated at room
temperature for 30min prior to use. The ﬁnal pDNA
concentration in the lipoplex dispersion was 0.126mg/ml.
Size andzeta potential measurements
The average particle size and zeta potential of the
liposomes, lipoplexes and polyplexes were measured by
photon correlation spectroscopy (PCS) (Autosizer 4700,
Malvern, Worcestershire, UK) and particle electrophor-
esis (Zetasizer 2000, Malvern), respectively. The liposome,
lipoplex and polyplex dispersions were diluted 40-fold in
Hepes buﬀer before the particle size and zeta potential
were measured. The average (standard error) of the
liposomes and lipoplexes was 1181 and 2426nm,
respectively and their average zeta potential equaled
264 and 141mV, respectively. The diameter and
zeta potential of the linear PEI polyplexes were 1654nm
en 332mV.
Cell viability assay
The inﬂuence of TCHD on the cell viability was
determined using the CellTiter-Glo Assay (Promega)
according to the manufacturer’s instructions. Brieﬂy,
2.510
4 cells/cm
2 were seeded in a 96-well plate and
allowed to adhere. After 24h, cells were washed with PBS
and incubated with serum-free medium containing
increasing amounts of TCHD. After 1h, the TCHD was
removed and replaced by culture medium. After 48h, the
plate was incubated at room temperature for 30min and
100ml CellTiter-Glo reagent was added to each well.
After shaking the plate for 10 and 2min incubation at
room temperature, the luminescence was measured on a
GloMax
TM 96 luminometer with 1s integration time.
Transfectionexperiments
Cells were seeded into 24-well plates at 2.510
4 cells/cm
2
and allowed to attach overnight. Subsequently, the culture
medium was removed, and after two washing steps with
serum-free medium, 0.4mg pDNA, polyplexes or lipo-
plexes (both containing 0.4mg pDNA) were added to each
well. After 2h the pDNA or non-viral nanoparticles were
removed from the cells and the cells were post-incubated
for 1h with serum-free medium containing increasing
amounts of TCHD. Subsequently, this medium was
replaced by culture medium and the cells were further
incubated at 378C. After 48h both the SEAP (or
luciferase) activity, as well as the total cellular protein
concentration were measured.
To determine the SEAP activity, 100ml of the culture
medium above the cells was taken and incubated at 658C
for 30min. Subsequently, 100ml dilution buﬀer (0.1M
glycine, 1mM MgCl2, 0.1mM ZnCl2, pH 10.4) and 15ml
4-methylumbelliferyl phosphate (4-MUP, 5.1mg/mli n
distilled water) was added. The obtained mixtures were
then incubated at 378C and the ﬂuorescence was measured
on a Wallac Victor2 ﬂuorescence plate reader (Perkin
Elmer-Cetus Life Sciences, Boston, MA) using an excita-
tion and emission wavelength of 360 and 449nm,
respectively.
To determine the luciferase activity of the cells, cells
were lysed with 80ml1 CCLR buﬀer (Promega) and
luciferase activity was determined with the Promega
luciferase assay kit according to the manufacturer’s
instructions. Brieﬂy, 100ml substrate was added to 20ml
sample and after a 2s delay, the luminescence was
measured during 10s with the GloMax
TM 96
luminometer.
To correct for the amount of cells per well, the protein
concentration was determined with the BCA kit (Pierce,
Rockford, IL, USA). Two hundred microliters mastermix,
containing 50 parts reagent A to 1 part B, was mixed with
20ml cell lysate and incubated at 378C for 30min and the
absorbance was measured on a Wallac Victor2 absorbance
plate reader (Perkin Elmer-Cetus Life Sciences) at 590nm.
Statistics
The experimental data in this report are expressed as mean
 standard deviation (SD). One way ANOVA was used to
determine whether data groups diﬀered signiﬁcantly from
each other. A P-value 50.05 was considered statistically
signiﬁcant.
RESULTS AND DISCUSSION
TCHDfacilitates the nuclearaccumulation of
dextransand plasmid DNA
It has been demonstrated that TCHD enhances the rate of
nuclear entry of the maltose binding protein (38).
However, this protein has a rather low molecular weight
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nucleus. Therefore, we studied whether TCHD could
induce nuclear entry of higher molecular weight com-
pounds like 158kDa dextrans and especially pDNA, since
nuclear transport of therapeutic genes forms an important
bottle neck in non-viral gene delivery.
In a ﬁrst approach we microinjected 158kDa TRITC-
dextrans in the cytoplasm of Vero cells and followed their
nuclear inﬂux in the absence and presence of TCHD by
confocal laser scanning microscopy (CLSM). In the
absence of TCHD, no TRITC-dextran could be detected
in the nucleus, not even after 1h of incubation (Figure 1A
and B). This is as expected, since it is well-known that
molecules larger than 70kDa cannot move passively
through the NPC network (41). When TRITC-dextran
microinjected cells were incubated with 1% (w/v) TCHD-
containing medium, a rapid nuclear localization of the
TRITC-dextrans was detected (Figure 1C till 1G). Indeed,
as soon as 10s after addition of TCHD to the cells,
TRITC-dextran was already detected in the nucleus. After
10min the TRITC-dextran ﬂuorescence was homoge-
neously distributed throughout the cell. These data clearly
demonstrate that TCHD opens the NPCs what results in
nuclear passage of macromolecules that otherwise are
excluded from the nucleus. We also co-injected TCHD
(2% w/v) and TRITC-dextran (158kDa) in the cytosol,
but under these conditions we could not observe nuclear
localization (data not shown). One likely explanation is
that TCHD, which is an amphiphilic compound and
contains a polar ethylene glycol moiety and an apolar
butylene moiety, can rapidly cross cell membranes and
thus becomes rapidly diluted in the surrounding medium
(38).
Next, we tested whether TCHD can also facilitate the
nuclear uptake of pDNA, since pDNAs are much larger
(2–10MDa) than 158kDa TRITC-dextran and have
dimensions in the range of the inner diameter of the
channels formed by the NPCs. When Cy5-pDNA was
microinjected in the cytoplasm of Vero cells, a ﬂuorescent
spot was visible at the injection site (Figure 2A, position
1). After 1h incubation with TCHD, we could not observe
accumulation of the pDNA inside the nucleus by CLSM
(data not shown). Importantly, during that time the
ﬂuorescent microinjection spot became more diﬀuse but
remained visible, indicating a restricted mobility of
pDNAs in the cytoplasm. This is in agreement with the
observations by Lukacs et al. (42) who showed that the
diﬀusion of pDNA in the cytoplasm may be an important
rate-limiting barrier in gene delivery utilizing non-viral
vectors. Hence, after 1h only a small fraction of the
microinjected pDNA will have reached the nuclear
membrane. Additionally, as stated earlier the inner
diameter of the NPC is in the size range of pDNA.
Therefore, even in the presence of TCHD the number of
pDNA molecules that enter the nucleus is probably low
and beyond the detection limit of the CLSM.
To monitor nuclear pDNA inﬂux with higher sensitiv-
ity, we used a CLSM equipped with a ﬂuorescence
correlation spectroscopy (FCS) set up, which can detect
as few as 1 ﬂuorescent molecule in a femtoliter range
confocal volume (43). We performed time-dependent
z-scans, perpendicular to the slide surface and through
position 2 (Figure 2A) before and after microinjection of
Cy5-pDNA in the cytoplasm at position 1 (Figure 2A),
hereby crossing ﬁrst a part of the cytoplasm beneath the
nucleus, then the nucleus and ﬁnally the cytoplasm above
the nucleus (Figure 2B). The black squares in Figure 2C
show that after cytoplasmic microinjection of the Cy5-
pDNA, a ﬂuorescence signal could be detected in the
cytoplasm, but not in the nucleus. The diﬀerence in
ﬂuorescence intensity detected below and above the
nucleus is most likely due to a diﬀerence in distance
from the cytosolic injection site. Subsequently, 1% (w/v)
TCHD was added to the cells and z-scans through
Figure 1. Non-confocal DIC (A, C and inserts in E till G) and confocal images (B and D till G) of Vero cells after cytosolic microinjection of
158kDa TRITC-dextran. Images (A) and (B) represent a microinjected cell 60min after microinjection. Images (C) till (G) represent another
microinjected cell after 10s (D), 40s (E), 5min (F) and 10min (G) incubation with 1% (w/v) TCHD.
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60min, represented by gray circles in Figure 2C, shows a
clear elevated Cy5-pDNA ﬂuorescence signal in the
nucleus compared to the ﬂuorescence proﬁle before
addition of TCHD. Subsequently, we studied the pDNA
inﬂux in the nucleus in the presence and absence of
TCHD. Therefore, the confocal volume of the FCS set up
was parked in the middle of the nucleus (at z-value
0.048mm). A gradual increase of Cy5-pDNA was
observed when TCHD was added to the cells
(Figure 2D; black circles). In contrast, when no TCHD
was present, no increase in ﬂuorescence could be detected
in the nucleus (Figure 2D; gray squares). This demon-
strates that the time-dependent increase in ﬂuorescence
after addition of TCHD is not a result of passive diﬀusion
of small degradation products of the Cy5-pDNA into the
nucleus.
Cytotoxicity ofTCHD
It has been demonstrated that the eﬀect of 7% (w/v)
TCHD on the NPC permeability is reversible and that
it does not cause denaturation or leakage of nucleo-
porins out of the NPCs (38). Nevertheless, the reversible
non-selective opening of NPCs may result into an
unwanted leakage of cellular biomacromolecules from
the cytoplasm into the nucleus or vice versa and hence
interfere with essential cellular processes. Therefore, to
ascertain that TCHD does not cause cytotoxic eﬀects, we
determined the cell viability 48h after exposure to TCHD
by the CellTiter-Glo assay (Promega). This assay
assesses the cytotoxicity by quantifying the intracellular
ATP levels, which is a sensitive marker of cell viability as
within minutes after a loss of membrane integrity, cells
lose the ability to synthesize ATP and endogenous
ATPases destroy any remaining ATP. Figure 3 shows
that incubation of Vero and A549 cells during 1h with 1%
(w/v) TCHD slightly reduced the viability of these cells.
These results demonstrate that the TCHD does not cause
drastic cytotoxic eﬀects under the conditions of the
nuclear uptake experiments above, i.e. incubation of the
cells with 1% (w/v) TCHD for 1h. Furthermore, we
noticed a cell-dependent TCHD sensitivity. Indeed,
TCHD at concentrations above 1% (w/v) signiﬁcantly
decreases the viability of Vero cells, whereas almost no
cytotoxic eﬀects are observed in A549 cells incubated with
up to 3% (w/v) TCHD.
Figure 2. Eﬀect of TCHD on the nuclear entry of microinjected Cy5-pDNA microinjected in the cytoplasm of Vero cells. A schematic overview of
the experimental set up is shown in (B). (A) Represents a microinjected cell with arrow (1) representing the place of cytoplasmic microinjection and
arrow (2) the place were the z-scan was performed. The black squares in (C) represent the z-scan through the cytosol and nucleus of a microinjected
Vero at time point zero, so just after microinjection and before addition of TCHD. The gray circles represent the z-scan 60min after addition of
1% (w/v) TCHD. In image (C), the center of the cell nucleus is located at z-value –0.048. The time-dependent increase of Cy5-pDNA ﬂuorescence in
the nucleus after cytoplasmic injection of Cy5-pDNA without (gray squares) and with (black circles) TCHD is shown in (D). The black circle in
(A) indicates the nuclear membrane.
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non-viral vectors
Since nuclear uptake of pDNA is considered as one of the
major barriers in non-viral gene delivery and since we
showed that TCHD could cause nuclear uptake of Cy5-
pDNA, we wondered whether TCHD could enhance the
transfection eﬃciency of naked pDNA, cationic poly-
plexes and lipoplexes. All transfection experiments were
performed in two cell types, namely A549 cells (lung
carcinoma cell line) and Vero cells (kidney epithelial cell
line), using diﬀerent TCHD concentrations.
The eﬀect of TCHD on the transfection eﬃciency of
naked pDNA was evaluated by incubating Vero and A549
cells with naked pDNA for 2h. Subsequently, pDNA that
was not incorporated into the cells was removed by
washing, and the cells were exposed to increasing
percentages (w/v) of TCHD for 1h (Figure 4). The
incubation with TCHD clearly increased the gene expres-
sion. This increase reached a maximal value at a TCHD
percentage of 0.5 and 1.5% in Vero (Figure 4A) and A549
cells (Figure 4B), respectively. At these optimal concen-
trations, a 3- and 66-fold increase in gene expression was
observed in Vero and A549 cells, respectively. At higher
percentages no further increase and even a drop in gene
expression was observed. Most likely this indicates that
TCHD at these concentrations aﬀects cellular processes
that are not detected by the MTT assay. Indeed, it has
been shown that the sensitivity of the MTT assay depends
on the mechanism causing cytotoxicity (44). Between 0
and 1.5% (w/v) TCHD, a gradual increase in gene
expression was observed in A549 cells (Figure 4B),
which may indicate that the extent of NPC opening
by TCHD is concentration dependent. Whether at 1.5%
(w/v) TCHD a maximal opening of the NPCs is reached is
not certain, since above this concentration also cytotoxic
eﬀects can play a role. This also explains the lower eﬀects
of TCHD in Vero cells. Indeed, in these cells the optimal
concentration of TCHD to increase gene transfer is 0.5%.
Based on the results in A549 cells, we can deduce that at
such low TCHD concentration the opening of the NPC
has not reached its maximum.
When TCHD was incubated together with the naked
pDNA, we also observed an increase in transfection
eﬃciency, but the eﬀect was less pronounced compared to
the post-incubation experiments described earlier (data
not shown). This could be expected as it takes some time
for pDNA to become internalized by the cells and released
from endocytotic vesicles into the cytoplasm.
Additionally, as cytosolic nucleases degrade pDNA, the
optimal moment to add TCHD to the cells is immediately
after the release of the pDNA in the cytoplasm.
To exclude that the higher gene expression was due to a
perforation of the cell membrane by TCHD, which would
allow an increased internalization of pDNA through the
plasma membrane, we tested whether TCHD causes
cytoplasmic entry of 158kDa TRITC-dextrans. Figure 5
shows that TRITC-dextrans did not enter the cells in the
absence nor in the presence of TCHD (1% w/v).
Consequently, we can state that after 1h incubation
TCHD does not cause membrane perforation.
In a next step, we analyzed the eﬀect of TCHD on the
transfection eﬃciency of linear PEI-based polyplexes, a
quite eﬃcient non-viral pDNA carrier that induces
endosomal release via the proton sponge mechanism
(45). Surprisingly, none of the incubation protocols with
TCHD resulted in a signiﬁcant increase in gene expression
mediated by linear PEI-based polyplexes even not
when the Vero and A549 cells were post-incubated with
2% (w/v) TCHD (Supplementary Figure 1A and B).
These data may indicate that, in agreement with Grosse
et al. (46), linear PEI-based polyplexes are mainly released
from the endosomes as intact complexes. Because of the
latter and taking into account the diameter of the linear
PEI-based polyplexes (165nm), TCHD is not expected
Figure 3. Cell viability of Vero (black) and A549 cells (gray) after 1h of incubation with TCHD. The asterix (
) represents data that signiﬁcantly
diﬀer (P50.05) from the data point 0% (w/v) TCHD.
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transfection eﬃcacy of such linear PEI-based polyplexes.
The endosomal escape mechanism of DOTAP:DOPE-
based lipoplexes is based on a diﬀerent mechanism and
results in the release of uncomplexed pDNA in the cytosol
(47). This implies that, when the free pDNA reaches the
nuclear membrane, TCHD should be able to induce its
nuclear translocation, similar to the naked pDNA
transfections. Therefore, we analyzed the eﬀect of
TCHD on the transfection eﬃciency of DOTAP:DOPE-
based lipoplexes. The same incubation protocols and cells
were used as in the experiments above. Incubating the cells
with TCHD for 1h immediately after incubation with the
lipoplexes, indeed caused an increase in transfection
eﬃciency in both Vero and A549 cells (Figure 6A and
B). A maximal increase was observed when the Vero and
A549 cells were incubated with 0.5 and 1.5% (w/v)
TCHD, respectively. This increase is lower than observed
with naked pDNA transfection, which can be attributed to
cell division. Compared to naked pDNA transfection,
transfection with lipoplexes introduces a higher amount of
pDNA in the cytoplasm, which can translocate to the
nucleus with higher probability either by entry through the
pores or during cell division. Hence, the few extra copies
that enter the nucleus after treating the cells with TCHD
will not tremendously increase gene expression. In
contrast, the amount of pDNA that reaches the cytoplasm
and subsequently the nucleus is extremely low in case of
naked pDNA transfection. Therefore, if TCHD can cause
nuclear translocation of only one pDNA molecule, this
eﬀect is much more spectacular.
CONCLUSION
In conclusion, our study demonstrates for the ﬁrst time
that the amphipathic alcohol TCHD can be employed to
enhance the nuclear uptake of pDNA by reversibly
collapsing the permeability barrier of the NPCs at non-
toxic concentrations. Furthermore, our transfection data
show that TCHD has huge potential to enhance especially
naked gene transfer. Although less eﬃcient than carrier-
mediated gene delivery, naked gene transfer is currently
Figure 4. Transfection eﬃciency of naked pDNA in Vero (A) and A549 (B) cells post-incubated for 1h with diﬀerent TCHD concentrations. The
asterisk (
) represents data that signiﬁcantly diﬀer (P50.05) from the data point 0% (w/v) TCHD.
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gene therapy clinical trials because of the higher safety
proﬁle, the simplicity of delivery, the lack of immune
responses and non-speciﬁc interactions in the body (with
e.g. extracellular matrices) (48). Naked gene transfer is
considered for DNA vaccination, Duchenne muscular
dystrophy, peripheral limb ischemia, and cardiac ische-
mia (49–52). Therefore, strategies that can enhance naked
gene transfer by enhancing nuclear uptake of DNA are
of huge interest. Additionally, we also want to remark
that TCHD is a metabolite of the drug candesartan
cilexetil (53) and of the solvent cyclohexanone, a
contaminant of intravenous dextrose and parenteral
feeding solutions (54), which possibly makes TCHD a
clinical acceptable adjuvant for naked gene transfer.
However, toxicology and in vivo gene transfer studies
are needed to conﬁrm the usefulness of this approach
for clinical applications.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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